EMA
approval
· 2026-08-07
EMA Authorised: Lacosamide Adroiq (lacosamide) — Extrovis EU Ltd
Summary
EMA has authorised Lacosamide Adroiq (lacosamide) for epilepsy with Extrovis EU Ltd as manufacturer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Epilepsy. MAH: Extrovis EU Ltd. Decision date: 07/08/2026